ArticleLeukemia2026

Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.

Marianne Ayoub et al.PubMed ↗Publisher ↗

No numbers read from the abstract.